Xponance’s TherapeuticsMD TXMD Stock Holding History

Xponance’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-371	Closed	-$7K	–	1230
2022 Q1	$7K	Buy	371 +3	+0.8%	+$47	﹤0.01%	1162
2021 Q4	$7K	Buy	368 +1	+0.3%	+$30	﹤0.01%	1170
2021 Q3	$14K	Sell	367 -13	-3%	-$577	﹤0.01%	1167
2021 Q2	$23K	Buy	+380	New	+$23K	﹤0.01%	1242
2020 Q3	–	Sell	-221	Closed	-$14K	–	1055
2020 Q2	$14K	Buy	+221	New	+$12.9K	﹤0.01%	1030

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Xponance's TXMD Position: Q2 2022 in Review

Xponance sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 371 shares — an estimated $7K sold.

Xponance first reported a position in TXMD in Q2 2020 and held it in 5 quarters. The position peaked at $23K in Q2 2021. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

Xponance reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
Xponance sold 371 TherapeuticsMD shares in Q2 2022, an estimated $7K.
Xponance first reported a position in TherapeuticsMD in Q2 2020 and held it in 5 quarters.
Xponance's TherapeuticsMD position peaked at $23K in Q2 2021.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Xponance's 13F filing for Q2 2022, filed 2 Aug 2022.